Litigation Details for In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

Docket		Date Filed	2021-09-09
Court	District Court, S.D. New York	Date Terminated	2025-12-19
Cause	28:0158 Notice of Appeal re Bankruptcy Matter (BA	Assigned To	Colleen McMahon
Jury Demand	None	Referred To
Patents	7,658,945
Link to Docket	External link to docket

Details for In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

Date Filed	Document No.	Description	Snippet	Link To Document
2021-09-09				External link to document
2021-09-09	158		ATTN: GENERAL COUNSEL U.S. PAT. NO. 7,658,945 DATED MARCH …relating to its patents for OxyContin and related efforts to preserve patent exclusivity; … Address 2. 2214 ASSIGNMENT OF CANADIAN PATENT 100027 … ABBOTT PARK, IL 60064-3500 2. 2220 PATENT LICENSE AGREEMENT AMONG … CHICAGO, IL 2. 2227 PATENT LICENSE AGREEMENT AMONG	External link to document

Litigation summary and analysis for: In Re: Purdue Pharma L.P. (S.D.N.Y. 2021)

Last updated: April 24, 2026

In re Purdue Pharma L.P. | 7:21-cv-07532: Litigation Summary and Patent-Impact Analysis

What case is 7:21-cv-07532 and what claims drove the litigation?

The docket caption “In re Purdue Pharma L.P.” under No. 7:21-cv-07532 is part of the 2019-2021 wave of federal litigation connected to Purdue Pharma’s opioid conduct and the resulting bankruptcy resolution and related disputes. The litigation’s factual core centers on marketing, distribution, and supply practices for OxyContin (oxycodone HCl) and the legal theories tied to public nuisance, state-law and federal consumer-protection style claims, and allegations of deception and diversion (including settlement and restructuring implementation disputes that followed).

In this posture, the legal battleground is less about a single patent’s validity or infringement and more about:

• Scope of Purdue’s exposure tied to the opioid business.
• Permissible settlement and release structures affecting claimants and third parties.
• Implementation enforceability of the bankruptcy deal terms that resolved broad liabilities.

Who were the key parties and how did the procedural path shape outcomes?

Across the coordinated Purdue litigation landscape, the practical party set usually includes:

• Purdue Pharma L.P. and affiliated debtors.
• State plaintiffs and governmental entities asserting opioid-related claims.
• Federal parties and other claimants whose claims intersected with bankruptcy plan releases.
• Objectors and parties challenging the bankruptcy settlement mechanics through federal court litigation.

The procedural path matters for patent strategy because the remedies drive leverage:

• Settlement mechanics and releases can preclude or narrow later pharmaceutical tort and market conduct actions.
• Bankruptcy discharge scope can reshape which future conduct-based claims survive and what theories remain available.

What did courts decide in this docket and what was the litigation impact?

For business planning, the critical take from Purdue’s docket cluster (including cases under the “in re” umbrella and related federal filings) is that federal courts repeatedly addressed the enforceability of bankruptcy plan terms and the treatment of released claims. That line of litigation narrowed the field of disputes that could proceed outside the bankruptcy resolution.

Patent impact: while patents are not typically the direct subject of the core Purdue settlement enforcement litigation, the outcomes affect IP value in two ways:

1. Market and litigation risk settlement changes the expected cost of enforcing or defending IP around the relevant product categories.
2. Plan releases can reduce exposure for conduct theories that often co-travel with IP disputes in opioid and pain-management markets (for example, claims framed around misrepresentation about formulation or abuse-deterrence attributes).

---

How does 7:21-cv-07532 connect to Purdue’s patent portfolio and opioid product lifecycle?

What opioid-product and formulation assets dominate Purdue’s patent estate?

Purdue’s IP stack historically centered on opioid formulations and abuse-deterrent technology (ADT) approaches, including:

• Extended-release oxycodone formulations (core OxyContin technology).
• Abuse-deterrent formulation concepts (physical and chemical deterrence strategies and combinations).
• Manufacturing and formulation process IP tied to controlled-release performance.

In typical opioid litigation, patents can appear in two buckets:

• Direct patent disputes (Hatch-Waxman-style ANDA challenges; infringement and validity).
• Market conduct litigation where product features, clinical claims, and abuse-deterrent performance become evidentiary issues even when patent validity is not litigated.

The Purdue settlement enforcement litigation (including the “in re” docket cluster) primarily constrains the second bucket by reducing the set of viable parties and claims outside the bankruptcy resolution.

How do bankruptcy releases change the IP litigation equation?

Even when patents are not directly adjudicated, releases can change the economics of patent enforcement. The mechanics typically operate as follows:

• If a release removes or limits claims against the reorganized entity and certain protected parties, then infringement leverage loses its collateral value for conduct-based pressure.
• If claims tied to product marketing or alleged misrepresentations are absorbed into plan resolution, then the evidentiary leverage from “product performance and deterrence” narratives weakens for later litigations.

For a patent analyst, the takeaway is not that patents vanish. It is that the conduct-litigation channel that often amplifies patent economics is narrowed.

---

What is the litigation relevance for current and future patent strategy?

Does 7:21-cv-07532 affect validity/infringement rulings?

The docket’s role in the Purdue litigation network is not primarily a forum for adjudicating the validity or infringement of specific Purdue patents. The dominant judicial focus is on settlement plan implementation, release scope, and whether objectors can unwind or limit the bankruptcy resolution.

Business impact for IP teams:

• You should treat 7:21-cv-07532 as a constraint on downstream litigation pathways, not as a roadmap for which specific patents survive.
• Patent strategy shifts toward clean-room enforcement of remaining intact rights rather than reliance on conduct narratives tied to bankruptcy-era claims.

How does it influence freedom-to-operate risk for competitors and generic entrants?

For competitors and generics assessing risk in the oxycodone/ADTs landscape, the practical effect is:

• Less uncertainty about who can sue and for what outside the bankruptcy plan.
• A more bounded universe of potential claims that can still be asserted.

That reduces tail-risk for market conduct theories, but it does not eliminate:

• Independent patent enforcement risks from any parties not protected by releases.
• Regulatory or product-liability pathways not covered by the plan terms.

---

Litigation timeline and decision cadence (high-level)

What were the main phases reflected by the docket cluster?

The Purdue litigation broadly unfolded in phases that show up across the federal docket ecosystem tied to “in re” matters:

1. Bankruptcy plan negotiation and initial approval proceedings
2. Objection rounds challenging release scope
3. Federal court decisions enforcing or limiting plan terms
4. Implementation disputes and enforcement actions

For 7:21-cv-07532 specifically, the actionable point is that it sits inside a continuing enforcement/implementation context rather than a stand-alone patent infringement trial.

---

Key legal themes that matter to IP stakeholders

What recurring themes control the outcome of Purdue-related “in re” litigation?

Across Purdue’s federal dispute set, the recurrent themes that move results are:

• Release scope: whether certain claims are barred by plan terms.
• Protected-party treatment: which third parties receive protection under the plan.
• Objector standing and procedural posture: whether challenges can proceed after approval.
• Enforceability: whether courts will require compliance with plan mechanics.

From an IP standpoint, these themes translate to one operational rule: reduce reliance on collateral conduct-litigation leverage and focus on enforceable patent rights.

---

Patent-value implications: what changes for investors and R&D planners

How does docket-level enforcement affect expected patent life economics?

When large-scale opioid litigation is resolved through bankruptcy settlement and enforced releases:

• Litigation discount rates for certain product-market narratives improve.
• Expected settlement pressure declines for conduct-style claims that would have complemented patent disputes.
• Commercial certainty increases for firms whose strategies depend on stable litigation boundaries.

But the IP-infringement risk component remains driven by:

• Whether relevant patents remain in force in the jurisdictions of interest.
• The remaining ability of parties to assert those patents notwithstanding plan releases.

How should IP teams reframe strategy after this docket’s enforcement line?

Teams should prioritize:

• Patent claim mapping tied to formulations and ADT mechanisms with clean evidentiary records.
• Defensive freedom-to-operate workflows that treat conduct-claim risk separately from patent risk.
• Portfolio pruning or continuation planning that anticipates that conduct-based leverage is lower, so infringement strength and market coverage matter more.

---

What can be inferred about Purdue’s patent posture from the litigation posture?

What does the “in re” litigation emphasis imply about the use of patents?

Because courts in the “in re” Purdue line focus on bankruptcy mechanics and release scope, the litigation posture implies that:

• Patent issues are not the primary driver in this docket’s adjudication.
• Purdue’s ability to preserve value depends more on settlement enforceability and market continuity than on winning a specific patent contest in this matter.

For patent analysts, that is a clear signal to keep two tracks separated:

• Track A (patents): enforceability, validity, claim coverage, and remaining term.
• Track B (litigation risk): releases, discharge, and which claims survive.

---

Key Takeaways

1. 7:21-cv-07532 sits in the Purdue bankruptcy enforcement orbit, where courts focus on plan implementation and release scope, not on adjudicating specific patent validity or infringement.
2. The main practical impact for IP stakeholders is not a change to which patents are valid, but a reduction and re-bounding of downstream litigation pathways that often amplify IP leverage.
3. After the “in re” enforcement line, patent strategy should treat conduct-litigation amplification as lower, with more emphasis on direct patent claim strength and jurisdiction-specific enforceability.
4. For R&D and investment decisions, the docket meaning is boundary-setting: who can sue, what claims survive, and where risk concentrates.

---

FAQs

1) Is 7:21-cv-07532 a patent infringement case?

No. The docket sits in the Purdue “in re” bankruptcy enforcement context centered on plan terms, releases, and dispute enforceability.

2) Does the case determine which Purdue patents are valid?

Not in any primary way. The litigation emphasis is on settlement and release mechanics rather than patent validity adjudication.

3) Will this docket eliminate patent litigation risk for generic or competitor products?

It can narrow conduct-claim tail risk tied to bankruptcy-era disputes, but it does not remove independent patent enforcement risks.

4) How should patent teams adjust tactics after this enforcement line?

Shift from relying on conduct-litigation narratives to building stronger, direct infringement/validity records tied to product features and jurisdiction-specific claim scope.

5) What is the investor takeaway from docket-level Purdue enforcement disputes?

Expected litigation tail-risk can decline when releases are enforced, but ongoing value depends on the remaining enforceable patent estate and product market boundaries.

---

References

[1] United States District Court, District of New Jersey. In re Purdue Pharma L.P., No. 7:21-cv-07532 (docket and related proceedings).